Dekkers: New Bayer Is Stable And Fit To Innovate for All Species
This article was originally published in Scrip
Much of Bayer AG's third quarter earnings call fixated on the group's recent reorganization to be a "life science only" company and the competitive benefits of this decision.
You may also be interested in...
German conglomerate says five recent launches led by Xarelto and Eylea are expected to bring in more than $11bn in peak sales, a 33% increase over previous projections. CEO Baumann pledges to make the investments needed to continue growing the pharma business.
Bayer AG is pursuing an acquisition of seed manufacturer Monsanto Co. that would establish agriculture as the largest business unit within the diversified life sciences company, usurping pharmaceuticals as the top revenue generator. Bayer Head of Innovation Kemal Malik said the company’s commitment to pharmaceuticals remains unwavering despite the M&A play.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.